Podcast: Palantir to sue Sadiq Khan, GSK’s $10bn mega-deal, and could the World Cup rescue pubs? Podcast In today’s episode of City PM’s Business As Usual podcast, we get stuck in the top stories of the day – from a major pharma M&A deal to a US software giant poised to take legal action against the Mayor of London. City Editor Simon Hunt gives his round up of major markets stories, as Pharma giant [...]
GSK says AI is reshaping drug pipeline as Nuvalent deal hits shares Tech GSK has said agentic AI is already affecting every asset in its pipeline, as pharmaceutical firms race to use the technology to cut the cost and risk of developing new medicines. Speaking at London Tech Week in Tuesday, Eyal Itskovits, GSK’s director of AI and machine learning, said that the technology has officially become a [...]
GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn Pharma Pharma giant GSK has sealed a $10bn deal to snap up Boston-based biopharmaceutical company Nuvalent. The FTSE 100 titan said it will pay $124 per share in cash in the agreement, marking a 40 per cent premium over what Nuvalent’s stock was trading at just before this announcement. The deal is expected to officially close [...]
Astrazeneca ploughs £300m into UK in surprise U-turn April 29, 2026 British drugs giant Astrazeneca has promised to plough £300m into its UK operations, just months after cancelling a nine-figure investment in a new lab after getting in a spat with the UK government over drug pricing. In a stunning volte-face, the UK’s largest pharmaceutical company said it would revive its £200m investment into a megalab [...]
FTSE 100 Live: Stocks drop as oil holds firm over $110; UK growth slashed April 29, 2026 Good morning and welcome back to the City PM liveblog. Oil prices are holding firm tipping over the $110 mark, bringing the cost of a barrel closer to the highs of $118 it peaked at earlier in the Iran war. Brent crude – the international benchmark for oil – advanced another one per cent on [...]
Global Counsel to be placed into administration February 19, 2026 Global Counsel’s 130 staff have been informed that the lobbying company founded by Peter Mandelson will be placed into administration as soon as tomorrow. City PM understands that despite a number of clients deciding to stay with the firm, the loss of business following the former US ambassador’s fall from grace has been substantial. A [...]
Global Counsel loses more clients as Epstein scandal deepens February 11, 2026 The crisis engulfing the lobbying firm founded by Peter Mandelson, Global Counsel, deepened on Tuesday, after three more of its blue-chip clients parted ways with the advisory over its links to co-founder Mandelson and the convicted sex trafficker Jeffrey Epstein. City PM understands that pensions giant Phoenix, Tesco and Bank of America have all severed [...]
GSK to acquire US biotech group for $2.2bn January 20, 2026 FTSE 100 giant GSK has reached an agreement to acquire US based biotech group Rapt Therapeutics. The deal values the company, which develops therapies for treating people with inflammatory and immunologic diseases, at $2.2bn (£1.6bn), and marks the first major deal for new GSK chief executive Luke Miels, coming just weeks after he took charge [...]
GSK strikes deal to cut drug prices with US government December 22, 2025 GSK has struck a voluntary agreement with the US government to lower the cost of prescription medicines and expand access to treatments for millions of Americans. The move comes as pressure mounts on global drugmakers over pricing, tariffs, and domestic investment. The London-listed pharma giant said the deal covers medicines used by over 40m US [...]
UK and US agree to zero tariff deal on pharmaceuticals December 1, 2025 The government has agreed to a major deal with Washington that will see the UK become the only country to secure zero import tariffs on pharmaceutical products into the US for at least three years. The deal follows months of negotiations between the government and the Trump administration, after the June trade deal left the [...]
